


Receipt date: 05/08/2007

10588857 - GAU: 1625  
MODIFIED PTO/SB/08 A & B (08-03)

Substitute for Form 1449 A & B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				Complete if Known	
				Application Number	10/588,857
				Confirmation Number	2021
				Filing Date	August 9, 2006
				First Named Inventor	Yusuke ISHII
				Art Unit	1751
				Examiner Name	Not yet assigned
Sheet	1	of	1	Attorney Docket Number	Q96496

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 2004/0138252	A1	07/15/2004	Ikeda et al.
		US 6,017,927	A	01/25/2000	Takeuchi et al.
		US			
		US			
		US			
		US			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		JP	2002-104968	A	10/04/2002		Yes
		WO	03/006019	A1	01/23/2003		With English abstract
		EP	0 801 067	A1	10/15/1997		English

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Shuichi NAKAGAWA et al., "Controlling Particle Size and Improving Fluidity of YM905 with Investigation of Crystallized Conditions" (2002) Japan Process Chemistry Association, pp. 85-86	Yes
		Christine E. HEADING, "Current Opinion in Central & Peripheral Nervous System Investigational Drugs" (2000), Vol. 2, No. 3, pp. 321-325	English
		"Treatment of Urinary Incontinence Muscarinic M <sub>3</sub> Antagonist" (1999), PROUS SCIENCE, Vol. 24, No. 8, pp. 871-874	English
		Ken Ikeda et al., "M <sub>3</sub> receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland" (2002) Naunyn-Schmiedeberg's Arch Pharmacol, Vol. 366, No. 2, pp. 97-103	English
		Seiji KOBAYASHI et al., "Effects of YM905, a Novel Muscarinic M <sub>3</sub> -Receptor Antagonist, on Experimental Models of Bowel Dysfunction In Vivo" (2001) Jpn. J. Pharmacol., Vol. 86, No. 3, pp. 281-288	English
		International Search Report dated March 2, 2005	

Examiner Signature	/Zinna Davis/ (08/24/2009)	Date Considered	
--------------------	----------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov), MPEP 901.04 or follow the hyperlink from the title of the document to the intranet. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ZD/